Diarrhoea

Low-cost rotavirus vaccine shows efficacy in Niger

Rotavirus gastroenteritis results in 37% of deaths caused by diarrhoea worldwide, but the cost and supply of available vaccines prevents their use in some countries, such as sub-Saharan Africa. A cheaper, live, oral bovine rotavirus pentavalent vaccine (BRV-PV) has now been developed and tested in a randomized, placebo-controlled trial in Niger. Healthy infants received three doses of either BRV-PV or placebo at 6, 10, and 14 weeks of age; the primary end point was the efficacy of vaccine versus placebo against a first episode of severe rotavirus gastroenteritis. Of 3,508 infants included in the per-protocol analysis, there were 31 cases of rotavirus gastroenteritis in the vaccine group and 81 cases in the placebo group. Thus, BRV-PV had an efficacy of 66.7% against rotavirus gastroenteritis. No significant between-group differences in the risk of adverse events were found.

References

  1. 1

    Isanaka, S. et al. Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1609462 (2017)

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dickson, I. Low-cost rotavirus vaccine shows efficacy in Niger. Nat Rev Gastroenterol Hepatol 14, 260 (2017). https://doi.org/10.1038/nrgastro.2017.50

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing